Page 221 - Read Online

Matsushita et al. Hepatoma Res 2018;4:61 I http://dx.doi.org/10.20517/2394-5079.2018.81 Page 15 of 17

Copyright
© The Author(s) 2018.

REFERENCES
1. Matsushita K, Tomonaga T, Kajiwara T, Shimada H, Itoga S, Hiwasa T, Kubo S, Ochiai T, Matsubara H, Nomura F. c-Myc suppressor FBP-
interacting repressor for cancer diagnosis and therapy. Front Biosci (Landmark Ed) 2009;1:3401-8.
2. Pelengaris S, Khan M, Evan GI. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenicproperties of Myc and
triggers carcinogenic progression. Cell 2002;109:321-34.
3. Bazar L, Meighen D, Harris V, Duncan R, Levens D, Avigan M. Targeted melting and binding of a DNA regulatory element by a
transactivator of c-Myc. J Biol Chem 1995;270:8241-8.
4. Michelotti GA, Michelotti EF, Pullner A, Duncan RC, Eick D, Levens D. Multiple single-stranded cis elements are associated with activated
chromatin of the human c-Myc gene in vivo. Mol Cell Biol 1996;16:2656-69.
5. Zubaidah RM, Tan GS, Tan SB, Lim SG, Lin Q, Chung MC. 2-D DIGE profiling of hepatocellular carcinoma tissues identified isoforms of
far upstream binding protein (FUBP) as novel candidates in liver carcinogenesis. Proteomics 2008;8:5086-96.
6. Malz M, Weber A, Singer S, Riehmer V, Bissinger M, Riener MO, Longerich T, Soll C, Vogel A, Angel P, Schirmacher P, Breuhahn
K. Overexpression of far upstream element binding proteins: a mechanism regulating proliferation and migration in liver cancer cells.
Hepatology 2009;50:1130-9.
7. Quinn LM. FUBP/KH domain proteins in transcription: back to the future. Transcription 2017;8:185-92.
8. Liu J, Akoulitchev S, Weber A, Ge H, Chuikov S, Libutti D, Wang XW, Conaway JW, Harris CC, Conaway RC, Reinberg D, Levens D.
Defective interplay of activators and repressors with TFIH in xeroderma pigmentosum. Cell 2001;104:353-63.
9. Kitamura A, Matsushita K, Takiguchi Y, Shimada H, Tada Y, Yamanaka M, Hiroshima K, Tagawa M, Tomonaga T, Matsubara H, Inoue
M, Hasegawa M, Sato Y, Levens D, Tatsumi K, Nomura F. Synergistic effect of non-transmissible Sendai virus vector encoding the c-Myc
suppressor FUSE-binding protein-interacting repressor plus cisplatin in the treatment of malignant pleural mesothelioma. Cancer Sci
2011;102:1366-73.
10. Kano M, Matsushita K, Rahmutulla B, Yamada S, Shimada H, Kubo S, Hiwasa T, Matsubara H, Nomura F. Adenovirus-mediated FIR
demonstrated TP53-independent cell-killing effect and enhanced antitumor activity of carbon-ion beams. Gene Ther 2016;23:50-6.
11. Mizokami D, Araki K, Tanaka N, Suzuki H, Tomifuji M, Yamashita T, Matsushita K, Shimada H, Shiotani A. Tacrolimus prevents
laryngotracheal stenosis in an acute-injury rat model. Laryngoscope 2015;125:E210-5.
12. Matsushita K, Shimada H, Ueda Y, Inoue M, Hasegawa M, Tomonaga T, Matsubara H, Nomura F. Non-transmissible Sendai virus vector
encoding c-Myc suppressor FBP-interacting repressor for cancer therapy. World J of Gastroenterol 2014;20:4316-28.
13. Mizokami D, Araki K, Tanaka N, Suzuki H, Tomifuji M, Yamashita T, Ueda Y, Shimada H, Matsushita K, Shiotani A. Gene therapy of
c-Myc suppressor FUSE-binding protein-interacting repressor by Sendai virus delivery prevents tracheal stenosis. PloS One 2015; doi:
10.1371/journal.pone.0116279.
14. Tanaka N, Araki K, Mizokami D, Miyagawa Y, Yamashita T, Tomifuji M, Ueda Y, Inoue M, Matsushita K, Nomura F, Shimada H, Shiotani
A. Sendai virus-mediated gene transfer of the c-Myc suppressor far-upstream element-binding protein-interacting repressor suppresses head
and neck cancer. Gene Ther 2015;22:297-304.
15. Black DL. Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem 2003;72:291-336.
16. Matsushita K, Takenouchi T, Shimada H, Tomonaga T, Hayashi H, Shioya A, Komatsu A, Matsubara H, Ochiai T. Strong HLA-DR antigen
expression on cancer cells relates to better prognosis of colorectal cancer patients: possible involvement of c-Myc suppression by interferon-
gamma in situ. Cancer Sci 2006;97:57-63.
17. Duriez M, Mandouri Y, Lekbaby B, Wang H, Schnuriger A, Redelsperger F, Guerrera CI, Lefevre M, Fauveau V, Ahodantin J, Quetier I,
Chhuon C, Gourari S, Boissonnas A, Gill U, Kennedy P, Debzi N, Sitterlin D, Maini MK, Kremsdorf D, Soussan P. Alternative splicing of
hepatitis B virus: a novel virus/host interaction altering liver immunity. J Hepatol 2017;67:687-99.
18. Rahmutulla B, Matsushita K, Satoh M, Seimiya M, Tsuchida S, Kubo S, Shimada H, Ohtsuka M, Miyazaki M, Nomura F. Alternative
splicing of FBP-interacting repressor coordinates c-Myc, P27Kip1/cyclinE and Ku86/XRCC5 expression as a molecular sensor for
bleomycin-induced DNA damage pathway. Oncotarget 2014;5:2404-17.
19. Rahmutulla B, Matsushita K, Nomura F. Alternative splicing of DNA damage response genes and gastrointestinal cancers. World J of
Gastroenterol 2014;20:17305-13.
20. Khageh Hosseini S, Kolterer S, Steiner M, von Manstein V, Gerlach K, Trojan J, Waidmann O, Zeuzem S, Schulze JO, Hahn S, Steinhilber
D, Gatterdam V, Tampé R, Biondi RM, Proschak E, Zörnig M. Camptothecin and its analog SN-38, the active metabolite of irinotecan,
inhibit binding of the transcriptional regulator and oncoprotein FUBP1 to its DNA target sequence FUSE. Biochem Pharmacol 2017;146:53-
62.
21. Brinkman BM. Splice variants as cancer biomarkers. Clin Biochem 2004;37:584-94.
22. Matsushita K, Tomonaga T, Shimada H, Shioya A, Higashi M, Matsubara H, Harigaya K, Nomura F, Libutti D, Levens D, Ochiai T.
An essential role of alternative splicing of c-Myc suppressor FUSE-binding protein-interacting repressor in carcinogenesis. Cancer Res
2006;66:1409-17.
23. Hastings ML, Allemand E, Duelli DM, Myers MP, Krainer AR. Control of pre-mRNA splicing by the general splicing factors PUF60 and
U2AF(65). PLoS One 2007;2:e538.
24. Page-McCaw PS, Amonlirdviman K, Sharp PA. PUF60: a novel U2AF65-related splicing activity. RNA 1999;5:1548-60.
25. Zhang YM, Yang HB, Shi JL, Chen H, Shu XM, Lu X, Wang GC, Peng QL. The prevalence and clinical significance of anti-PUF60
antibodies in patients with idiopathic inflammatory myopathy. Clin Rheumatol 2018;37:1573-80.